NCCN Guideline Recommendations for Post‑Operative Management of Follicular Thyroid Carcinoma

Surgical Decision‑Making

Completion thyroidectomy should be performed within 6–12 weeks after the initial lobectomy, followed by risk‑stratified treatment based on tumor characteristics. (National Comprehensive Cancer Network) 1
Indications for completion thyroidectomy include any of the following high‑risk features: tumor size > 4 cm, positive resection margins, gross extrathyroidal extension, or macroscopic multifocal disease. (National Comprehensive Cancer Network) 1
Lobectomy alone may be sufficient when all of the following low‑risk criteria are met: tumor size ≤ 4 cm, no history of prior radiation exposure, no distant metastases, and no extrathyroidal extension. (National Comprehensive Cancer Network) 1

Obtain a neck ultrasound to assess the remaining thyroid lobe and detect possible cervical lymph‑node metastases. (National Comprehensive Cancer Network) 1
Measure baseline serum thyroglobulin and anti‑thyroglobulin antibodies 6–12 weeks after surgery to establish a reference for future surveillance. (National Comprehensive Cancer Network) 1

For patients with high‑risk disease, target a suppressed TSH < 0.1 mIU/L using levothyroxine therapy. (National Comprehensive Cancer Network) 1
For low‑risk disease, aim for a low‑normal TSH range of 0.5–2 mIU/L. (National Comprehensive Cancer Network) 1

Serial serum thyroglobulin measurements every 6–12 months constitute the most important tool for detecting recurrence or metastasis. (National Comprehensive Cancer Network) 2

Systemic therapy with lenvatinib (preferred) or sorafenib is recommended for progressive, radioactive‑iodine‑refractory disease. (National Comprehensive Cancer Network) 2
Isolated resectable bone metastases should be embolized prior to surgical removal to reduce intra‑operative hemorrhage risk. (National Comprehensive Cancer Network) 2

Follicular thyroid carcinoma (FTC) is the second most common thyroid cancer after papillary thyroid carcinoma (PTC), with incidence rates remaining relatively stable over the past 30 years 3, 4
The WHO classifies FTC into three categories based on invasion pattern: minimally invasive, angioinvasive, and widely invasive, with varying prognoses 5, 6

FTC cannot be readily diagnosed with fine-needle aspiration (FNA) cytology alone and is typically classified as "indeterminate" in thyroid cytology reporting schemes 5, 7
Definitive diagnosis requires histological evidence of capsular and/or vascular invasion, which can only be determined after surgical excision 8

FTC is typically unifocal (not multifocal) at presentation, contrasting with PTC, which is more commonly multifocal 5, 6

The WHO classification of FTC into minimally invasive, angioinvasive, and widely invasive categories is based on invasion pattern and has implications for prognosis 5, 6, 9